Breaking News Instant updates and real-time market news.

BAYRY

Bayer

$34.24

-0.37 (-1.07%)

, JNJ

Johnson & Johnson

$133.19

0.3 (0.23%)

06:21
10/06/17
10/06
06:21
10/06/17
06:21

Bayer keeping forecast for peak Xarelto annual sales, Reuters reports

Despite new study results, Bayer is keeping its forecast for peak Xarelto annual sales, Reuters reports. Reference Link

BAYRY

Bayer

$34.24

-0.37 (-1.07%)

JNJ

Johnson & Johnson

$133.19

0.3 (0.23%)

  • 08

    Oct

  • 17

    Oct

  • 23

    Oct

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

BAYRY Bayer
$34.24

-0.37 (-1.07%)

08/18/17
UBSW
08/18/17
DOWNGRADE
Target $128
UBSW
Neutral
Monsanto downgraded to Neutral from Buy at UBS
UBS analyst John Roberts downgraded Monsanto (MON) to Neutral saying the shares are now less than 10% away from the accepted Bayer (BAYRY) offer of $128. The analyst calculates that the market is currently pricing in a 70% chance of the deal going through. His view that the deal could be approved remains unchanged. Approvals of peer deals suggest antitrust approval likely for Monsanto, Roberts tells investors in a research note. The analyst keeps a $128 price target for Monsanto shares.
09/05/17
BERN
09/05/17
NO CHANGE
BERN
Bernstein still sees 'very high' probability of Bayer, Monsanto deal approval
Bernstein analyst Jeremy Redenius notes that the European Commission has opened an in-depth review of the Bayer (BAYRY)/Monsanto (MON) deal due to concerns of reduced competition in pesticides, seeds, and traits. The analyst believes this is not surprising, as the in-depth review is the norm for deals of this size. Comparing the EC's initial concerns with those of the Dow/DuPont (DWDP) deal, he still sees a "very high" probability of deal approval.
09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.
10/03/17
RHCO
10/03/17
NO CHANGE
RHCO
TG Therapeutics has positive read through from Bayer approval, says SunTrust
SunTrust analyst Yatin Suneja believes that the FDA's decision to grant accelerated approval to Bayer's (BAYRY) Aliqopa, a PI3K-delta inhibitor, as a treatment for Relapsed/Refractory Follicular Lymphoma, bodes well for TG Therapeutics' (TGTX) own PI3K-delta inhibitor, TGR-120. The analyst says that the lack of a black box warning on Bayer's Aliqopa shows that not all PI3K-delta inhibitors have the safety issues that have been attributed to them in the past. Suneja says that "Aliqopa's approval reflects positively on TGR-1202, which offers best-in-class safety , and provides clarity on TGR-1202's regulatory pathway in" lymphoma The analyst says that investors are "overlooking" its potential in " lymphoma, and keeps a Buy rating on the shares.
JNJ Johnson & Johnson
$133.19

0.3 (0.23%)

09/25/17
09/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) initiated with a Neutral at Citi. 2. CoreSite Realty (COR) initiated with a Neutral at JPMorgan. 3. Hi-Crush Partners (HCLP) initiated with an Overweight at Piper Jaffray. 4. Zillow (Z, ZG) initiated with a Neutral at Macquarie. 5. Big Lots (BIG) initiated with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/17
SBSH
10/03/17
NO CHANGE
SBSH
Citi's general surgery survey 'very positive' for Intuitive Surgical
Citi analyst Amit Hazan says his firm's general surgery survey is "very positive" for Intuitive Surgical (ISRG), and "much less so" for Medtronic (MDT) and Johnson & Johnson (JNJ). Robotic procedures are expected to be up about 30% this year and next, with ventral hernia leading, Hazan tells investors in a research note partially titled "It's a Good Time to be a Robot." He believes robotic is really starting to hurt laparoscopy and that Medtronic and J&J will likely be forced to talk about the headwind publicly.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.

TODAY'S FREE FLY STORIES

02:40
12/12/17
12/12
02:40
12/12/17
02:40
General news
FX Update: Narrow ranges have prevailed »

FX Update: Narrow ranges…

01:55
12/12/17
12/12
01:55
12/12/17
01:55
General news
FX Action: USD-JPY has plied a narrow 14 pip range »

FX Action: USD-JPY has…

NAV

Navistar

$40.07

0.17 (0.43%)

20:13
12/11/17
12/11
20:13
12/11/17
20:13
Upgrade
Navistar rating change at Stifel »

Navistar upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

GBT

Global Blood Therapeutics

$44.78

-0.925 (-2.02%)

20:10
12/11/17
12/11
20:10
12/11/17
20:10
Conference/Events
Global Blood Therapeutics to hold an investor webcast »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VMW

VMware

$121.09

1.52 (1.27%)

19:55
12/11/17
12/11
19:55
12/11/17
19:55
Conference/Events
VMware management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 17

    Jan

MMC

Marsh & McLennan

$83.93

-0.2 (-0.24%)

19:52
12/11/17
12/11
19:52
12/11/17
19:52
Conference/Events
Marsh & McLennan management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BG

Bunge

$69.67

-0.12 (-0.17%)

19:48
12/11/17
12/11
19:48
12/11/17
19:48
Conference/Events
Bunge management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

COP

ConocoPhillips

$51.69

0.12 (0.23%)

19:42
12/11/17
12/11
19:42
12/11/17
19:42
Conference/Events
ConocoPhillips management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

BL

BlackLine

$35.04

0.37 (1.07%)

19:36
12/11/17
12/11
19:36
12/11/17
19:36
Conference/Events
BlackLine management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 26

    Feb

AGIO

Agios Pharmaceuticals

$61.42

0.45 (0.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SGEN

Seattle Genetics

$55.27

-3.995 (-6.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Seattle Genetics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 16

    Dec

TCBK

TriCo Bancshares

$41.34

-0.3 (-0.72%)

19:15
12/11/17
12/11
19:15
12/11/17
19:15
Hot Stocks
TriCo to acquire FNB in transaction valued at roughly $315.3M »

TriCo Bancshares and FNB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:53
12/11/17
12/11
18:53
12/11/17
18:53
Hot Stocks
Archrock Partners LP names Raymond Guba interim CFO of general partner »

Archrock Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AROC

Archrock

$9.80

0.3 (3.16%)

, APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:49
12/11/17
12/11
18:49
12/11/17
18:49
Hot Stocks
Archrock names Raymond Guba Interim CFO »

Archrock announced that…

AROC

Archrock

$9.80

0.3 (3.16%)

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAV

Advantage Oil & Gas

$4.05

0.05 (1.25%)

18:33
12/11/17
12/11
18:33
12/11/17
18:33
Hot Stocks
Advantage Oil & Gas announces 2018 capital budget of $175M »

Advantage Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

18:22
12/11/17
12/11
18:22
12/11/17
18:22
Upgrade
Rosneft rating change at Goldman Sachs »

Rosneft upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$24.85

-1.11 (-4.28%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Piper sees 'another…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FATE

Fate Therapeutics

$4.14

-0.03 (-0.72%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Hot Stocks
Fate Therapeutics reports Day 100 results from Phase 1 stage of PROTECT trial »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GM

General Motors

$41.67

-0.35 (-0.83%)

18:14
12/11/17
12/11
18:14
12/11/17
18:14
Periodicals
GM CEO: Cutting EV tax credit 'will have an impact' on sales, Reuters says »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

EDIT

Editas Medicine

$23.60

-1.36 (-5.45%)

18:02
12/11/17
12/11
18:02
12/11/17
18:02
Hot Stocks
Editas Medicine reports results from expanded CRISPR genome editing strategies »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$39.09

0.42 (1.09%)

18:00
12/11/17
12/11
18:00
12/11/17
18:00
Hot Stocks
First Mid-Illinois Bancshares to acquire First BancTrust Corp for $73.8M »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$120.42

0.5 (0.42%)

17:46
12/11/17
12/11
17:46
12/11/17
17:46
Initiation
Chevron initiated  »

Chevron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPOR

Gulfport Energy

$13.13

0.67 (5.38%)

17:44
12/11/17
12/11
17:44
12/11/17
17:44
Initiation
Gulfport Energy initiated at Credit Suisse »

Gulfport Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$57.13

0.75 (1.33%)

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Initiation
EQT Corporation initiated at Credit Suisse »

EQT Corporation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

, BITCOIN

Bitcoin

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Hot Stocks
SEC Chairman says no initial coin offerings have been registered »

Securities and Exchange…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.